GO:1901491 negative regulation of lymphangiogenesis: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901491 (negative regulation of lymphangiogenesis) describes any process that stops, prevents, or reduces the frequency, rate, or extent of lymphangiogenesis.
• Key negative regulators include Tenascin-C (TNC), which delays inflammation resolution by suppressing lymphatic vessel growth, and Apolipoprotein A-I (APOA1), which limits TNF-mediated lymphangiogenesis.
• Pro-inflammatory cytokines such as TNF and VEGF family members are central to the balance between pro- and anti-lymphangiogenic signaling.
• Dysregulated negative regulation of lymphangiogenesis contributes to chronic inflammation, tumor metastasis, and cardiovascular disease.
• Experimental models for studying this process include knockout mice, cytokine-treated cell cultures, and immunohistochemical analysis of tissues.
• CRISPR-based knockout, knock-in, and overexpression models enable precise interrogation of genes that negatively regulate lymphangiogenesis.
Description
Lymphangiogenesis is the formation of new lymphatic vessels from pre-existing ones, a process essential for tissue fluid homeostasis, immune cell trafficking, and lipid absorption. The Gene Ontology term GO:1901491, negative regulation of lymphangiogenesis, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of lymphangiogenesis. This regulatory process is critical for preventing excessive lymphatic growth, which can contribute to pathological conditions such as chronic inflammation, tumor metastasis, and cardiovascular disorders. Understanding the molecular players that negatively regulate lymphangiogenesis is therefore of broad biomedical interest. Recent studies have identified Tenascin-C as a negative regulator that delays the resolution of inflammation by suppressing lymphangiogenesis. Similarly, Apolipoprotein A-I has been shown to limit the negative effect of tumor necrosis factor on lymphangiogenesis. These findings highlight the importance of negative regulatory mechanisms in maintaining lymphatic homeostasis. This article synthesizes current knowledge on GO:1901491, covering its definition, key genes, regulatory mechanisms, disease relevance, and experimental approaches for research.
negative regulation of lymphangiogenesis At A Glance
| GO ID | GO:1901491 |
|---|---|
| GO term | negative regulation of lymphangiogenesis |
| Ontology | biological_process |
| Synonym | inhibition of lymphangiogenesis; downregulation of lymph vessel formation |
| Major function | Suppression of lymphatic vessel formation |
| Key negative regulators | Tenascin-C (TNC), Apolipoprotein A-I (APOA1) |
| Related processes | Inflammation resolution, tumor metastasis, cardiovascular disease |
| Experimental models | Knockout mice, cytokine-treated cells, immunohistochemistry |
What Is GO:1901491?
GO:1901491, negative regulation of lymphangiogenesis, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of lymphangiogenesis. It encompasses molecular events that inhibit the sprouting, proliferation, migration, or tube formation of lymphatic endothelial cells, thereby limiting the growth of new lymphatic vessels.
Why Is negative regulation of lymphangiogenesis Important in Cell Biology?
Negative regulation of lymphangiogenesis is crucial for preventing excessive lymphatic vessel growth, which can exacerbate inflammation, promote tumor metastasis, and contribute to cardiovascular pathology. Understanding this process provides insights into disease mechanisms and identifies potential therapeutic targets for modulating lymphatic function.
• Prevents chronic inflammation by limiting lymphatic hyperplasia.
• Restrains tumor-associated lymphangiogenesis, reducing metastatic spread.
• Modulates immune cell trafficking and fluid balance.
• Influences resolution of inflammation in conditions like atherosclerosis.
• Plays a role in dental pulp inflammation and repair.
• Affects wound healing, particularly in diabetic wounds.
• Provides targets for anti-lymphangiogenic cancer therapy.
• Helps maintain corneal avascularity and tissue transparency.
• Regulates lymphangiogenesis in response to cytokines like TNF and VEGF.
• Offers experimental entry points for CRISPR-based gene editing.
What Happens During negative regulation of lymphangiogenesis?
Initiation by negative regulators
In simple terms: Certain molecules act as brakes on lymphatic vessel growth.
Negative regulation of lymphangiogenesis begins when inhibitory molecules such as Tenascin-C or Apolipoprotein A-I are expressed or activated in the tissue microenvironment. These factors can be induced by inflammatory signals or tissue damage, and they act to counter pro-lymphangiogenic stimuli.
Inhibition of lymphatic endothelial cell proliferation
In simple terms: The brakes slow down the multiplication of cells that form lymphatic vessels.
Negative regulators can directly suppress the proliferation of lymphatic endothelial cells (LECs). For example, Tenascin-C has been shown to inhibit LEC proliferation, thereby reducing the number of cells available for vessel formation. This step is critical for limiting the extent of lymphangiogenesis.
Blockade of sprouting and migration
In simple terms: The brakes prevent existing lymphatic vessels from sprouting new branches and moving.
Negative regulation also targets the sprouting and migration of LECs. Cytokines such as TNF can negatively affect lymphangiogenesis, and molecules like Apolipoprotein A-I can limit this effect. This blockade prevents the extension of lymphatic networks into surrounding tissues.
Modulation of VEGF signaling
In simple terms: The brakes interfere with growth factor signals that tell lymphatic vessels to grow.
VEGF receptors are key transducers of lymphangiogenic signals. Negative regulation of lymphangiogenesis often involves dampening VEGF receptor signaling pathways, either by reducing ligand availability or by inhibiting downstream signaling components. This modulation ensures that lymphatic growth is tightly controlled.
Resolution of inflammation
In simple terms: The brakes help end inflammation by stopping new lymphatic vessel growth.
By limiting lymphangiogenesis, negative regulators such as Tenascin-C delay the resolution of inflammation, as excessive lymphatic growth can perpetuate inflammatory responses. This step highlights the interplay between lymphatic vessel formation and immune regulation.
Key Genes Involved in GO:1901491 negative regulation of lymphangiogenesis
The following genes and proteins have been experimentally implicated in the negative regulation of lymphangiogenesis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNC | Tenascin-C inhibits LEC proliferation and delays inflammation resolution | Knockout mice show enhanced lymphangiogenesis |
| APOA1 | Apolipoprotein A-I limits TNF-mediated lymphangiogenesis | Overexpression reduces lymphangiogenesis |
| TNF | Pro-inflammatory cytokine that can negatively affect lymphangiogenesis | Modulation of TNF signaling alters lymphatic growth |
| VEGFC | Lymphangiogenic growth factor; negative regulators may oppose its action | Target for inhibition in cancer |
| VEGFR3 | Receptor for VEGFC/D; negative regulators may downregulate its signaling | Key node in lymphangiogenesis |
| VEGFA | Can influence lymphangiogenesis; negative regulators may counteract | Implicated in tumor lymphangiogenesis |
| VEGFR2 | Receptor for VEGFA; cross-talk with lymphangiogenesis | Target for anti-lymphangiogenic therapy |
| PROX1 | Master transcription factor for LEC fate; negative regulators may suppress its activity | Essential for lymphatic development |
| FOXC2 | Transcription factor involved in lymphatic valve formation; may be modulated | Mutations cause lymphedema |
| LYVE1 | LEC marker; expression may be reduced by negative regulators | Used to assess lymphangiogenesis |
| PDPN | Podoplanin, LEC marker; negative regulators may affect its expression | Marker for lymphatic vessels |
| CCL21 | Chemokine involved in immune cell trafficking; may be affected | Links lymphangiogenesis and immunity |
| IL6 | Cytokine that can modulate lymphangiogenesis | Inflammatory mediator |
| IL10 | Anti-inflammatory cytokine; may influence negative regulation | Immunomodulation |
| TGFB1 | Transforming growth factor beta; can inhibit lymphangiogenesis | Potential negative regulator |
| IFNG | Interferon gamma; can suppress lymphangiogenesis | Immune-mediated regulation |
| HIF1A | Hypoxia-inducible factor; may drive pro-lymphangiogenic signals opposed by negative regulators | Oxygen sensing |
How Is negative regulation of lymphangiogenesis Regulated?
Negative regulation of lymphangiogenesis is itself controlled by a network of cytokines and signaling pathways. Pro-inflammatory cytokines such as TNF can induce negative regulators like Tenascin-C, which in turn suppress lymphangiogenesis. Apolipoprotein A-I modulates the effect of TNF on lymphangiogenesis, suggesting a feedback loop. VEGF receptor signaling is a central node that is often targeted by negative regulatory mechanisms. Additionally, hypoxia and metabolic factors can influence the balance between pro- and anti-lymphangiogenic signals.
negative regulation of lymphangiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNC | Chronic inflammation, fibrosis | TNC knockout mouse |
| APOA1 | Atherosclerosis, cardiovascular disease | APOA1 transgenic mouse |
| VEGFC | Cancer metastasis, lymphedema | VEGFC overexpression |
| TNF | Inflammatory diseases | TNF knockout mouse |
| PROX1 | Lymphedema, lymphatic dysplasia | PROX1 conditional knockout |
Chronic Inflammation
Negative regulation of lymphangiogenesis by Tenascin-C delays the resolution of inflammation, contributing to persistent inflammatory states. This mechanism is relevant to diseases such as atherosclerosis, where lymphangiogenesis plays a complex role.
Cancer Metastasis
Tumor-associated lymphangiogenesis facilitates metastatic spread, and negative regulators can potentially restrain this process. Modulation of lymphangiogenesis by immunotherapy approaches is an active area of research in triple-negative breast cancer.
Cardiovascular Disease
Lymphangiogenesis is involved in coronary atherosclerosis, and its negative regulation may influence plaque progression and stability. Apolipoprotein A-I, a negative regulator, is also a key component of HDL, linking lipid metabolism to lymphatic function.
Wound Healing
In diabetic wound healing, negative-pressure wound therapy induces lymphangiogenesis, suggesting that negative regulators may be downregulated to promote healing. Impaired lymphangiogenesis is a feature of chronic wounds.
From negative regulation of lymphangiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate lymphangiogenesis? | Knockout mouse or CRISPR KO in LECs |
| Does a point mutation in gene X alter its inhibitory function? | Point-mutation knock-in mouse |
| Can overexpression of gene X suppress lymphangiogenesis? | Transgenic overexpression or viral delivery |
| Where is gene X expressed during lymphangiogenesis? | Tagged knock-in reporter mouse |
| What is the effect of gene X on LEC proliferation? | In vitro LEC culture with CRISPR KO |
| Does gene X modulate VEGF signaling? | Co-culture and signaling assays |
How to Study the negative regulation of lymphangiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunohistochemistry | Lymphatic vessel density and marker expression | Tissue analysis |
| CRISPR knockout | Gene function loss | In vitro and in vivo |
| Tube formation assay | LEC network formation | In vitro lymphangiogenesis |
| Proliferation assay | LEC growth | Negative regulator testing |
| Migration assay | LEC motility | Inhibitory effect assessment |
| RNA-seq | Global gene expression changes | Pathway discovery |
| Proteomics | Protein abundance and modifications | Signaling analysis |
| Western blot | Protein expression and phosphorylation | VEGF signaling |
Immunohistochemistry
Immunohistochemical analysis using markers such as LYVE1 and PDPN allows visualization and quantification of lymphatic vessels in tissues, enabling assessment of negative regulation in vivo.
CRISPR-Cas9 Knockout
CRISPR-Cas9 mediated knockout of candidate negative regulators in lymphatic endothelial cells or mouse models can determine their functional role in lymphangiogenesis.
Cytokine and Growth Factor Assays
Treating LECs with cytokines such as TNF or VEGFC and measuring proliferation, migration, and tube formation can reveal negative regulatory mechanisms.
Transcriptomics and Proteomics
RNA-seq and proteomics of LECs under conditions that induce or inhibit lymphangiogenesis can identify novel negative regulators and pathways.
How CRISPR Can Be Used to Study GO:1901491 negative regulation of lymphangiogenesis
Knockout
CRISPR-Cas9 knockout of genes such as TNC or APOA1 in lymphatic endothelial cells or mouse models can abolish their negative regulatory function, leading to enhanced lymphangiogenesis. This approach is essential for establishing causality.
Point Mutation
Introducing specific point mutations in candidate negative regulators can dissect domain-specific functions, such as receptor binding or enzymatic activity, without completely removing the protein.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) into endogenous loci allows real-time tracking of negative regulator expression and localization during lymphangiogenesis.
Overexpression
CRISPR activation or transgenic overexpression of negative regulators like APOA1 can suppress lymphangiogenesis, providing gain-of-function evidence.
How EDITGENE Supports negative regulation of lymphangiogenesis Research
Researchers studying negative regulation of lymphangiogenesis-related genes often need to determine whether a candidate gene is causally involved in suppressing lymphatic vessel growth. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lymphangiogenesis research.
Frequently Asked Questions About negative regulation of lymphangiogenesis
What is GO:1901491?
GO:1901491 is the Gene Ontology term for negative regulation of lymphangiogenesis, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of lymphangiogenesis.
What genes are involved in negative regulation of lymphangiogenesis?
Key genes include TNC (Tenascin-C), APOA1 (Apolipoprotein A-I), and cytokines such as TNF, which can inhibit lymphangiogenesis.
How does Tenascin-C negatively regulate lymphangiogenesis?
Tenascin-C inhibits lymphatic endothelial cell proliferation and delays the resolution of inflammation, thereby suppressing lymphangiogenesis.
What is the role of Apolipoprotein A-I in lymphangiogenesis?
Apolipoprotein A-I limits the negative effect of TNF on lymphangiogenesis, acting as a negative regulator.
Which diseases are associated with negative regulation of lymphangiogenesis?
Chronic inflammation, cancer metastasis, cardiovascular disease, and impaired wound healing are associated with dysregulated negative regulation of lymphangiogenesis.
How can I study negative regulation of lymphangiogenesis in the lab?
Common methods include immunohistochemistry for lymphatic markers, CRISPR knockout of candidate genes, and cytokine assays in lymphatic endothelial cells.
What are the markers for lymphatic vessels?
LYVE1 and PDPN (podoplanin) are commonly used markers for lymphatic endothelial cells.
Can CRISPR be used to study negative regulation of lymphangiogenesis?
Yes, CRISPR-Cas9 knockout, knock-in, and overexpression models are powerful tools to dissect gene function in lymphangiogenesis.
What is the role of VEGF signaling in lymphangiogenesis?
VEGF receptors transduce signals that promote lymphangiogenesis; negative regulators often interfere with this pathway.
How does inflammation affect lymphangiogenesis?
Inflammation can induce both pro- and anti-lymphangiogenic factors; negative regulators like Tenascin-C can delay inflammation resolution by suppressing lymphangiogenesis.
Conclusion
Negative regulation of lymphangiogenesis (GO:1901491) is a critical biological process that maintains lymphatic homeostasis and prevents pathological lymphatic growth. Key regulators such as Tenascin-C and Apolipoprotein A-I have been identified, and their mechanisms are being unraveled. Dysregulation of this process contributes to inflammation, cancer, and cardiovascular disease, making it an attractive therapeutic target. Continued research using CRISPR-based models and advanced imaging will further illuminate the molecular players and pathways involved, paving the way for novel interventions.
References
- 1. Katoh D et al.. 2025. Negative regulation of lymphangiogenesis by Tenascin-C delays the resolution of inflammation.. iScience 28(2):111756 PMID: 39925433
- 2. Sáinz-Jaspeado M et al.. 2018. Cytokines regulating lymphangiogenesis.. Curr Opin Immunol 53:58-63 PMID: 29680577
- 3. Feng X et al.. 2022. The Role of Lymphangiogenesis in Coronary Atherosclerosis.. Lymphat Res Biol 20(3):290-301 PMID: 34714136
- 4. Alani NA et al.. 2025. Differential Regulation of Angiogenesis, Lymphangiogenesis, and Neural Tissue in Normal and Inflamed Dental Pulp: Immunohistochemical Analysis.. Diagnostics (Basel) 15(14) PMID: 40722568
- 5. Guerrero-Sánchez M et al.. 2026. Modulation of tumor-associated lymphangiogenesis by combination immunotherapy approaches in triple-negative breast cancer: a systematic review.. Front Immunol 17:1641259 PMID: 42093995
- 6. Bisoendial R et al.. 2015. Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis.. Arterioscler Thromb Vasc Biol 35(11):2443-50 PMID: 26359513
- 7. Shibuya M et al.. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.. Exp Cell Res 312(5):549-60 PMID: 16336962
- 8. Wu M et al.. 2023. Negative-Pressure Wound Therapy Induces Lymphangiogenesis in Murine Diabetic Wound Healing.. Plast Reconstr Surg 151(4):779-790 PMID: 36729939
